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Abstract
Background: Pluripotent stem cells, such as embryonic stem cells or induced pluripotent stem cells, have a great
potential for regenerative medicine. Induced pluripotent stem cells, in particular, are suitable for replacement of
tissue by autologous transplantation. However, tumorigenicity is a major risk in clinical application of both
embryonic stem cells and induced pluripotent stem cells. This study explores the possibility of manipulating the cell
cycle for inhibition of tumorigenicity.
Methods: We genetically modified mouse induced pluripotent stem cells (miPSCs) to overexpress p27 tumor
suppressor and examined their proliferation rate, gene expression, cardiac differentiation, tumorigenicity, and
therapeutic potential in a mouse model of coronary artery ligation.
Results: Overexpression of p27 inhibited cell division of miPSCs, and that inhibition was dependent on the
expression level of p27. p27 overexpressing miPSCs had pluripotency characteristics but lost stemness earlier than
normal miPSCs during embryoid body and teratoma formation. These cellular characteristics led to none or smaller
teratoma when the cells were injected into nude mice. Transplantation of both miPSCs and p27 overexpressing
miPSCs into the infarcted mouse heart reduced the infarction size and improved left ventricular function.
Conclusions: The overexpression of p27 attenuated tumorigenicity by reducing proliferation and earlier loss of
stemness of miPSCs. The overexpression of p27 did not affect pluripotency and differentiation characteristics of
miPSC. Therefore, regulation of the proliferation rate of miPSCs offers great therapeutic potential for repair of the
injured myocardium.
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Background
Cell therapy with embryonic stem cells (ESCs) or in-
duced pluripotent stem cells (iPSCs) is one of the prom-
ising cures to repair damaged tissues and organs in a
variety of clinical settings [1]. However, the major con-
cern for the clinical use of ESCs and iPSCs is their abil-
ity to induce teratoma derived from all three germ layers
when injected into immunodeficient mice [2]. Teratoma
formation is caused by the self-renewal capability of
undifferentiated transplanted cells. Therefore, prediffer-
entiation of the stem cells and elimination of undifferen-
tiated stem cells before transplantation are important
considerations to prevent potential tumorigenesis [3, 4].
However, it is rather difficult to remove the relatively
few undifferentiated cells completely from millions of
differentiating cells.
One of the main causes of tumorigenesis is uncon-
trolled cell cycle progression. Cell cycle progression is
governed by cyclin dependent kinases (cdk) that are acti-
vated by cyclin binding and inhibited by the cdk inhibi-
tors [5, 6]. p27 is one of the major members of the cdk
inhibitor protein family and inhibits the cyclin–CDK
complex; for example, cyclin E-cdk2, and cyclin D-cdk4
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and -cdk6 complexes [7–9]. Studies with p27 knockout
mice that developed multiple organ hyperplasia indicate
that p27 has antiproliferative activity [10]. It is reported
that reduced expression of p27 is frequently observed in
various cancers [11–13] and correlates with poor prog-
nosis [14–16]. From these studies, it is clear that p27 is
a promising target for tumor therapies. In fact, it is re-
ported that overexpression of p27 suppresses tumor
growth in various cancers [13, 17, 18] and reduces pro-
liferation of human and murine ESCs [19, 20].
In this report, we overexpressed p27 in mouse iPSCs
(miPSCs) and explored its potential for reducing the
proliferation rate of miPSCs in vitro and in vivo and
their differentiation into cardiac phenotypes. Further-
more, the therapeutic potential for reducing myocardial
infarction in vivo was also investigated.
Methods
Animals
All animal experiments conformed to The Guidelines
for Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication
No. 85–23, revised 1985), and all protocols of animal ex-
periments were approved by the Institutional Animal
Care and Use Committee, University of Cincinnati.
Materials
The lentivirus vector for expression of mVenus-hGemnin
(pCSII-EF-mVenus-hGem) was provided by Dr. Atsushi
Miyawaki (RIKEN, BSI) [21]. Monomeric red fluorescent
protein (mRFP) [22] gene cloned into pcDNA3 (Invitro-
gen) was a gift from Dr. Doug Golenbock (University of
Massachusetts Medical School) (Addgene Plasmid
13032). Mouse ESCs (mESCs) from C57BL/6 mice were
purchased from GIBCO (S1503-100).
Gene construction
CMV-promoter and neomycin resistance genes were
cloned into the SalI site of pSMPUW (CellBiolab) to
make pSMPUWneo. EF1α promoter was cloned from
pEF-E2-Crimson (Clontech) and inserted into XhoI-
EcoRI site of pTetOff (Clontech) to make pTetOff-EF1α.
The EF1α promoter and tet-responsible transcriptional
activator (tTA) from pTetOff-EF1α were cloned into SalI
site of pSMPUWneo to make pSMPUWneo-TetOff. p27
gene was cloned from rat cDNA. p27 and mRFP were
connected with Thoseaasigna virus 2A peptide and
inserted in ERI-BamHI site of pTRET-tight (Clontech).
The TRET promoter and p27-2A-mRFP were cut out
from pTRE-tight and inserted in pGEM-T-easy (Pro-
mega). The TRET promoter and p27-2A-mRFP were
cut out from pGEM-T-easy and inserted into EcoRI
site of pSMPUWneo-TetOff to make pSMPUWneo-
TRET-p27-TetOff.
Transient and stable transfection
To produce lentivirus, pCSII-EF-mVenus-hGem, pCgpV
(Cell Biolabs), pRsv-Rev (Cell Biolabs), and pCMV-
VSVG (Cell Biolabs) were transfected to HEK293Ta cells.
The supernatant was concentrated using an ultracentrifuge
and added to mESCs. mVenus-hGemini expressing clone
was selected using fluorescence. To establish the stable cell
line of p27-2A-mRFP, pSMPUWneo-TRET-p27-TetOff was
digested by XhoI, and the linearized plasmid was trans-
fected into miPSCs [23] with Lipofectamine 2000 (Life
Technologies). p27-2A-mRFP expressing clone was selected
by resistance to Geneticin (100 μg/ml; Roche) at first, then
selection was done using fluorescent active cell sorting
(FACS). The stable cell line was designated as miPSCs-p27.
Transient transfection of pSMPUW-TRET-p27-TetOff to
miPSCs and mESCs was done with Xfect (Clontech),
Lipofectamine 2000 (Life Technologies), or Lipofectamine
3000 (Life Technologies) transfection reagents.
Cell culture, cell proliferation, trypan blue staining,
embryoid body formation, and spontaneous cardiac
differentiation
miPSCs from C57BL/6 mice [23] and mESCs were cul-
tured with knockout Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies) supplemented with leukemia
inhibitory factor (LIF; Millipore), 15 % knockout serum
replacement, nonessential amino acids, L-glutamine, 2-
mercaptoethanol, and penicillin/streptomycin (Life Tech-
nologies). To determine the proliferation rate, miPSCs
and miPSCs-p27 were dispersed by accutase (Life Tech-
nologies). Cells were then stained with trypan blue (Life
Technologies) and counted manually using a hematocyt-
ometer. Trypan blue stained cells were counted as dead
cells.
Embryoid body (EB) formation was performed as de-
scribed [24]. Briefly, miPSCs were dispersed into single
cells with accutase and were suspended with differenti-
ation medium which consisted of high-glucose DMEM
(Fisher Scientific) supplemented with 20 % fetal bovine
serum (Life Technologies), nonessential amino acids, L-
glutamine, 2-mercaptoethanol, and penicillin/strepto-
mycin. The cells were then transferred to plastic Petri
dishes, where they aggregated to form EBs and were cul-
tured in suspension for 9 days.
Spontaneous differentiation from miPSCs to cardio-
myocytes was performed as described [25]. Briefly, 500
miPSCs or 1000 miPSCs-p27 in 20 μl aliquots sus-
pended in differentiation medium were cultured in
hanging drops to form EBs for 2 days. Individual EBs
were transferred to a 96-well ultralow attachment plate
(Corning) and incubated for 3 days. EBs were then
transferred to gelatin-coated 48-well culture plates and
incubated for 9 days. To evaluate the differentiation effi-
ciency of miPSCs and miPSCs-p27, 48-well plates were
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monitored each day under a microscope to detect the
appearance of spontaneously contracting cardiomyocytes.
Immunocytochemistry
p27-2A-mRFP transient expressing miPSCs were fixed
by 4 % formaldehyde and stained by DAPI for detecting
mRFP expression and nuclei. To detect overexpression
of p27, fixed p27-2A-mRFP transient expressing miPSCs
were incubated with rabbit anti-p27 antibody (Abcam,
ab32034) and stained by Alexa Fluor 488 conjugate goat
anti-rabbit antibody (Life Technologies) and DAPI.
Imaging
Image acquisition was performed with an inverted
microscope (IX71 Olympus, BioStation Nikon). For
time-lapse imaging, miPSCs (4 × 104) were seeded on
35-mm glass bottom dishes covered with mouse embry-
onic fibroblasts (MEFs). After 6 hours of incubation,
pSMPUW-TRET-P27-TetOff was transfected to the
cells. On the next day, the dish was examined on a BioS-
tation (Nikon), and real time fluorescent imaging was
performed to count the divisions of individual mRFP ex-
pressing cells with 5 % CO2 at 37 °C for 24 hours. Data
analysis was performed with ImageJ for IX71 and Nis-
Element (Nikon) for Biostation.
RNA isolation and reverse transcription
Total RNA was purified using an RNeasy kit (Qiagen);
0.2 μg of total RNA was used for the reverse transcrip-
tion reaction with Omniscript RT kit (Qiagen) according
to the manufacturer’s instructions. Polymerase chain re-
action (PCR) was performed with Taq DNA polymerase
(Qiagen). The primer sequences used are given in
Additional file 1: Table S1.
Flow cytometry analysis
miPSCs or miPSCs-p27 (1 × 106 cells) were seeded onto
MEFs in a 60-mm dish. After 2 days, the cells were dis-
sociated using Accutase (Life Technologies) and fixed in
80 % ethanol for 1 hour. Fixed cells were washed with
phosphate-buffered saline (PBS) and then resuspended
with DAPI-containing solution (1 μg/ml DAPI, 0.1 %
Triton X-100 in PBS) for 30 minutes at room
temperature for nuclear staining. The stained cells were
analyzed by FACSAria II (BD). More than 10,000 cells
were collected for analysis of each cell cycle phase. The
number of each cell cycle phase was analyzed by the
Dean and Jett model [26] with Igor pro software
(WaveMetrics).
Teratoma formation
Immunodeficient nude mice were purchased from Jackson
Laboratories, USA. The procedure for assessing teratoma
formation in nude mice was approved by the University of
Cincinnati Animal Care And Use Committee. Undifferen-
tiated miPSCs or miPSCs-p27 (1 × 106 cells) were sus-
pended with 100 μl of matrigel (BD) and were injected
subcutaneously into 2- to 3-month-old nude mice. Four
weeks after injection, teratomas were fixed with 10 % for-
malin and processed for hematoxylin and eosin staining
for histological evaluation.
Myocardial infarction and cell transplantation
A model of acute myocardial infarction was developed
in allogenic 8- to 12-week-old male C57BL/6 J immuno-
competent mice as described earlier [27]. Briefly, the an-
imals were anesthetized (ketamine/xylazine 80 mg/kg
and 20 mg/kg body weight, respectively, intraperitone-
ally), intubated, and mechanically ventilated (Harvard
Rodent Ventilator, Model 683). Minimally invasive
thoracotomy was performed for permanent ligation of
the left anterior descending artery (LAD) with a Prolene
#8.0 suture. Myocardial ischemia was confirmed by color
change of the left ventricular wall. The animals were
grouped as follows: group 1 was untreated (control, n = 5);
intramyocardial injection of 10 μl basal DMEM containing
1 × 105 cells from EBs derived from miPSCs or miPSCs-
p27 were performed for the animals of group 2 (n = 4) or
group 3 (n = 5), respectively. The cells were injected 10
minutes after LAD ligation at the peri-infarction site in
the free wall of the left ventricle (LV) under direct vision.
The chest was closed and the animals were allowed to re-
cover. Subsequently, the animals were injected with bupri-
nex (0.05 ml subcutaneously) during the first 24 hours to
alleviate pain and were maintained until 4 weeks before
euthanasia and sampling of the heart tissue.
Physiologic assessment of heart function
Transthoracic echocardiography was performed to
evaluate heart function at 4 weeks after the respective
treatments using iE33 equipped with a 15- to 7-MHz
broadband transducer (Philips Ultrasound, Bothell, WA).
Intraperitoneal anesthesia was administered with 0.1 %
ketamine and 0.02 % xylene per body weight (g) for
anesthesia. The animals (group1, n = 5; group 2, n = 4;
group 3, n = 5) were anesthetized (approximately 3 mi-
nutes) and placed supine onto an imaging platform. The
distal extremities were taped gently to electro pads that
provide continuous electrocardiographic and heart rate
(pulse detection) measurements. The heart was imaged
in the two-dimensional mode in the parasternal long-axis
and/or parasternal short-axis views, which were subse-
quently used to position the M-mode cursor perpendicu-
lar to the ventricular septum and LV posterior wall, after
which M-mode images were obtained. For each animal,
measurements were obtained from 4–5 consecutive heart
cycles. Measurements of ventricular anterior thickness,
LV internal dimension, and LV posterior wall thickness
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were made from two-dimensionally directed M-mode
images of the LV in both systole and diastole. Ejection
fraction was measured based on the area–length
method after measurement of LV internal area and dis-
tance from apex to basal LV in both systole and diastole.
The scoring system was patterned after the American
Society of Echocardiography’s scoring system which is
used conventionally in interpreting clinical echocardio-
graphic studies.
Histological studies
For measurement of infarction size (and area of fibrosis),
the hearts were arrested in diastole by intravenous injec-
tion of cadmium chloride and fixed in 10 % buffered for-
malin. The heart was excised, cut transversely, and
embedded in paraffin for Masson’s trichrome staining.
Infarct size was defined as the sum of the epicardial and
endocardial infarct circumference divided by sum of the
total LV epicardial and endocardial circumferences using
computer-based planimetry with Image-J analysis soft-
ware (version 1.6; NIH). The pathology specimens of
teratomas were assessed by a pathologist.
Statistical analysis
All values are expressed as mean ± standard error.
Statistical difference between the considered groups
was evaluated by Student’s t-test or Tukey-Kramer
multiple-comparison test. A P value <0.05 was consid-
ered significant.
Results
Inhibition of proliferation in p27 expressing miPSCs
cDNA of p27 in miPSCs was transiently transfected to
investigate the effect of p27 overexpression. p27 express-
ing cells could be detected with red fluorescence by
combining cDNAs of p27 and mRFP with 2A peptide
gene. The overexpressions of mRFP and p27 were con-
firmed by fluorescence of mRFP and immunostaining of
p27 (Fig. 1a and b). Figure 1c and d shows time lapse
images of proliferation of the transient transfected
miPSCs over 24 hours. Because of the low transfection
efficiency (~1 %), most of the miPSCs did not exhibit
mRFP expression. Phase contrast images show expan-
sion of the surface area of miPSC colonies due to prolif-
eration of cells (Fig. 1c). On the contrary, the p27
overexpressing miPSCs did not divide throughout the
imaging period (Fig. 1d). Figure 1e shows the relation-
ship between fluorescent intensity of mRFP (expression
level of p27) and number of cell divisions over 24 hours
with a negative correlation. In the mRFP intensity range
of 0 to 500, some cells showed a higher number of divisions
than those of control miPSCs (2.4 ± 0.4). In the mRFP in-
tensity range of 500 to 3000, all cells showed a lower num-
ber of divisions than those in control miPSCs. The p27
overexpressing cells with mRFP intensities more than 1000
exhibited no cell division during real time imaging (Fig. 1e).
To maximize the number of miPSCs overexpressing p27, a
stable p27 overexpressing cell line was developed (miPSCs-
p27; Fig. 1f) using FACS (Figure S1 in Additional file 2).
The proliferation rate of miPSCs-p27 was slower than that
of miPSCs. The number of miPSCs-p27 cells 3 days after
seeding on gelatin coated dishes was less than that of
miPSCs (Fig. 1g). Because the percentage of trypan blue
stained miPSCs-p27 was the same as that of miPSCs, the
reduced proliferation rate in miPSCs-p27 was not due to
cell death (Fig. 1h).
The population of G1 phase cells was increased in
miPSCs-p27
Since the proliferation rate of miPSCs was decreased by
p27 overexpression, we investigated the effect of cell
cycle phases in pluripotent stem cells by p27 overexpres-
sion. First, we used mESCs to assess the effect of p27
overexpression on cell cycle progression in pluripotent
stem cells. To measure the cell cycle changes, we made
a cell line which stably expressed a cell cycle sensor
mVenus-hGeminin in mESCs [21]. Expression level of
hGeminin oscillates during proliferation of the cells due
to cell cycle-dependent proteolysis by ubuiquitin-
proteasomal systems. hGeminin level is high during S to
M phases and low in G1 phase (Fig. 2a) [21]. The degree
of hGeminin expression was not uniform amongst the
cells (Fig. 2b and c) because cell cycles of mESCs were
not synchronized. We observed that most of the p27 ex-
pressing red fluorescent cells had low green fluorescence
(Fig. 2d and e). Figure 2f and g shows profiles and aver-
age values of mVenus fluorescence, respectively. Both of
the graphs clearly show a low level of green fluorescence
amongst the population of p27 overexpressing mESCs
compared to p27 nonoverexpressing cells (Fig. 2f and g).
This result suggests that p27 overexpression resulted in
more cells at G1 phase in mESCs.
miPSCs-p27 also showed an increase in the population
in the G1 phase by p27 overexpression. Figure 2h shows
the flow cytometry analysis of miPSCs-p27. There were
two peaks in the flow cytometry results of miPSCs in the
left panel of Fig. 2h. The left and right peaks originated
from the cells in G1 and G2 phases, respectively. The
cells between the peaks represented the cells in S phase.
Compared to miPSCs, the G1 peak was wider in
miPSCs-p27 (right panel in Fig. 2h). Figure 2i shows the
number of cells in each phase of the cell cycle. There
were significant differences in G1 and S phases between
miPSCs-p27 and miPSCs (G1: miPSCs 30.2 ± 6.1 %,
miPSCs-p27 60.8 ± 15.8 %, P < 0.01; S: miPSCs 56.5 ± 14.1
%, miPSCs-p27 30.8 ± 15.2 %, P < 0.05; student t-test).
These results clearly show that overexpression of p27
arrested more cells at G1 phase, which was consistent
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with the ability of p27 to suppress G1–S transition by in-
hibition of cyclin D and E [28].
EB formation and cardiac differentiation of miPSCs-p27
RT-PCR analysis of pluripotent marker genes was
performed to investigate the effect of p27 overex-
pression on pluripotency of miPSCs. Expression of
p27 in miPSCs-p27 was almost 10 times higher than
that of miPSCs (Figure S2A in Additional file 3)
and results were consistent with the results of p27
overexpression in mESCs and p27 null miPSCs
[19, 29]. There was no significant difference in ex-
pression of Oct4, Nanog, Sox2, and cMyc in miPSCs
and miPSCs-p27 (Figure S2A and B in Additional file 3),
suggesting that p27 overexpression did not affect
the pluripotency characteristics of miPSCs. This was
determined in miPSCs and miPSCs-p27 to test the
effect of p27 overexpression on differentiation. To
Fig. 1 Proliferation of p27 overexpressing miPSCs. Overexpression of p27-2A-mRFP in transient transfected miPSCs are shown with mRFP fluorescence
(a) and immunostaining of p27 (b) with nuclear staining by DAPI. The bar represents 100 μm. c, d Time lapse images of phase contrast (c) and mRFP
(d) in p27-2A-mRFP transfected miPSCs. e Relationship between the number of cell divisions and intensities of mRFP in p27-2A-mRFP expressing miPSCs
(closed circles). An open circle shows the average of the number of cell divisions in control miPSCs (n = 3). Dotted line shows fitting line of results of
p27-2A-mRFP expressing cells with exponential function. f Phase contrast (left) and mRFP fluorescent (right) images of miPSCs-p27. g Proliferation rate of
miPSCs (closed circles) and miPSCs-p27 (open circles). h Comparison of the percentages of trypan blue stained cells between miPSCs and miPSCs-p27.
Error bars correspond to the SEM (n = 3). *P< 0.05, student’s t-test. mRFP monomeric red fluorescent protein
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account for low proliferation, a two-fold higher initial cell
number was used for miPSCs-p27 compared to miPSCs
in hanging drops. miPSCs-p27 formed EBs with a shape
similar to miPSCs (Fig. 3a–d). The limited number of EBs
formed by miPSCs-p27 might be due to their slower pro-
liferation rate (Figure S3A in Additional file 4). Spontan-
eously beating EBs were observed both from miPSCs and
miPSCs-p27 (Fig. 3f–h). There was no difference in the
frequency of spontaneously beating EBs amongst miPSCs
and miPSCs-p27 (Figure S3B in Additional file 4), suggest-
ing no inherent difference in their ability to differentiate
into cardiac myocytes. Linearized plasmid DNA tends
to integrate into the transcriptional active site of host
genome. Therefore, the expression of transgene is some-
times lost after differentiation. We observed a distinct
mRFP signal in EBs arising from miPSCs-p27 (Fig. 3b).
However, the expression of mRFP was not clear in differ-
entiated cardiac myocytes (Fig. 3f), suggesting that the
transgene was integrated into a stem cell-specific gene
locus. The induction of cardiac marker genes (GATA4,
cTnT, Mef2c) in miPSCs-p27 were similar to EBs from
miPSCs as determined by EB formation assays and
spontaneous cardiac differentiation assays (Fig. 3i and
j). The expression of pluripotency genes using EB for-
mation assay was different in miPSCs and miPSCs-
p27. The expression of Oct4, Sox2, and Nanog was
Fig. 2 The cell cycle of p27 overexpressing mESCs. a Schematic representation of the cell cycle sensor, Fucci. Expression of mVenus-hGeminin
can be seen during S to M phases. b–e Images of phase contrast (b), mVenus (c), mRFP (d), and merge of mVenus and mRFP (e) of p27-2A-mRFP
transfected mESCs stably expressing mVenus-hGeminin. f Profiles of fluorescent intensities of mVenus-hGeminin in p27-2A-mRFP expressing (black
bars) and nonexpressing (white bars) mESCs. g Averaged fluorescent intensities of mVenus-hGeminin in p27-2A-mRFP expressing and nonexpressing
mESCs. Error bars correspond to the SEM (n = 3). **P< 0.01, student’s t-test. h Flow cytometry data of DAPI stained miPSCs (left) and miPSCs-p27 (right).
i Populations of each phase of cell cycle in miPSCs and miPSCs-p27. White bars show G1, gray bars show S, and dark gray bars show G2 phases. Error bars
correspond to the SEM (n = 3). miPSC mouse induced pluripotent stem cell, miPSCs-p27 p27 overexpressing mouse induced pluripotent stem cells, RFP
red fluorescent protein
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reduced during EB formation. There was a significant
decrease in Oct4 and Sox2 on the ninth day of EB formation
by p27 overexpressing iPSCs (Fig. 3k and l). Compared to
the initial expression level, cMyc expression was three times
higher on the third day of EB formation by miPSCs. In
contrast, the induction of cMyc expression was 1.5 times
higher on the third day in miPSCs-p27. The expression of
cMyc was gradually decreased both in miPSCs and
miPSCs-p27, and it was significantly less in miPSCs-
p27 than miPSCs on the ninth day of EB formation
Fig. 3 Differentiation of miPSCs-p27. a–d Images of EBs from miPSCs and miPSCs-p27 on the sixth day of EB formation. Fluorescent images of
miPSCs and miPSCs-p27 are shown in (a) and (b), respectively. Phase contrast images of miPSCs and miPSCs-p27 are shown in (c) and (d),
respectively. e–h Images of beating EBs from miPSCs and miPSCs-p27. Fluorescent images of miPSCs and miPSCs-p27 are shown in (e) and (f),
respectively. Phase contrast images of miPSCs and miPSCs-p27 are shown in (g) and (h), respectively. i, j Expression of GATA-4, cTnT, and Mef2c
after EB formation is shown. RT-PCR analysis of the genes (i) and relative intensities of the mRNA to GAPDH expression (j) of EBs from miPSCs and
miPSCs-p27 are shown. High expressions of the genes were detected in beating EBs derived from miPSCs or miPSCs-p27. *P < 0.05, comparison to 0
days of miPSCs with Tukey-Kramer test. k, l Expression of pluripotent marker genes are shown. RT-PCR analysis of stem cell marker genes (k) and
relative intensities (l) of miPSCs and miPSCs-p27 are shown. *P < 0.05, student’s t-test. Error bars correspond to the SEM (n = 3). m, n Protein expression
of pluripotent marker genes are shown. Western blots of stem cell marker genes (m) and relative intensities (n) of miPSCs and miPSCs-p27 are shown.
*P < 0.05, student’s t-test. Error bars correspond to the SEM (n = 3). EB embryoid body, miPSC mouse induced pluripotent stem cell, miPSCs-p27 p27
overexpressing mouse induced pluripotent stem cells
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(Fig. 3k and l). Similar results were also obtained at
the protein level for Oct4, Nanog, and cMyc on the
ninth day of EB formation by p27 overexpressing
iPSCs (Fig. 3m and n).
Teratoma formation by miPSCs-p27
miPSCs-p27 normally differentiated into cardiac myo-
cytes despite the presence of pluripotency genes. Terato-
mas were formed in mice injected with either miPSCs or
miPSCs-p27, and comprised of tissues consisting of
three germ layers (Fig. 4a–f ), consistent with RT-PCR
data. The sizes of teratomas in miPSCs-p27 injected
nude mice were significantly smaller than that of miPSC
injected nude mice (Fig. 4g–k). Four and seven independ-
ent experiments were done for miPSCs and miPSCs-p27,
respectively. However, while we observed teratomas in
all miPSC injected mice, we could find teratomas only
in four of seven miPSCs-p27 injected mice (see Figure
S4 in Additional file 5 for all teratomas from miPSCs
or miPSCs-p27). Transient overexpression of p27 by
intramuscular injection of miPSCs also attenuated the
teratoma formation (Figure S5 in Additional file 6). Fig-
ure 4l and m shows the expression of pluripotent
marker genes in teratomas of miPSC and miPSC-p27
injected nude mice. Teratomas contained undifferenti-
ated stem cells as detected by expression of Oct4, Sox2,
Nanog, and cMyc. However, the expression levels of
pluripotency genes were significantly less in miPSC-p27
derived teratomas (Fig. 4l and m).
Effect of miPSCs-p27 on functional recovery of the
ischemic hearts in vivo
To evaluate the therapeutic potential of miPSCs-p27 for
the recovery of cardiac function in the ischemic hearts
in vivo, we transplanted miPSCs or miPSCs-p27 into the
infarcted mouse hearts. All animals survived the full
length of the study, and there were no deaths related to
cell transplantation. Animals (DMEM, n = 5; miPSCs, n
= 5; and miPSCs-p27, n = 4) were euthanized at 4 weeks
after the respective treatments. Transplantation of both
miPSCs and miPSCs-p27 in and around the infarcted
myocardium attenuated infarct size expansion compared
with the DMEM-treated group (DMEM, 47.9 ± 9.9 %;
miPSCs, 22.9 ± 7.0 %; and miPSCs-p27, 23.3 ± 2.1 %;
Fig. 5a and b). We also performed echocardiography to
evaluate LV function after cell transplantation. The in-
dexes of LV contractile function were well preserved in
the miPSC and miPSC-p27 groups, including LV end-
diastolic volume (DMEM, 112.2 ± 5.7 ml; miPSCs, 60.1
± 9.8 ml; and miPSCs-p27, 61.3 ± 4.1 ml; Fig. 5c), LV
end-systolic volume (DMEM, 81.2 ± 6.7 ml; miPSCs,
35.1 ± 6.4 ml; and miPSCs-p27, 34.7 ± 2.2 ml; Fig. 5d),
and LV ejection fraction (DMEM, 28.0 ± 3.6 %; miPSCs,
40.7 ± 2.3 %; and miPSCs-p27, 43.2 ± 1.2 %; Fig. 5e).
Discussion
Transplantation of pluripotent stem cells in the infarcted
heart produces malignant tumors. The tumorigenicity is
a major risk of cell therapy and is due to abnormal pro-
liferation of pluripotent stem cells. Therefore, prevention
of proliferation is a potentially effective approach for
clinical use of pluripotent stem cells. Accordingly, we
proposed that the overexpression of p27 in miPSCs
would reduce tumorigenicity. We show that overexpres-
sion of the cdk inhibitor p27 reduced proliferation of
mouse pluripotent stem cells and increased the popula-
tion of the cells in the cell cycle at the G1 phase. The
overexpression of p27 slowed transition from G1 to S
phase and increased the population of the cells in the
G1 phase. These results are consistent with studies on
p27 overexpression in cancer cells, and also human and
mouse ESCs [17, 19, 20]. It is known that the protein
level of p27 is largely regulated by proteolysis [30] which
rises during G1 phase progression while the protein level
is kept low through the S/G/M phases. The proteolysis
may affect the p27 protein level in miPSCs-p27 and pro-
motes slower cell cycle progression.
p27 overexpression did not affect composition of plur-
ipotency genes of miPSCs-p27. Our results are consist-
ent with other reports that overexpression of p27 did
not affect the expression of pluripotency genes in human
ESCs [19] and is also not sufficient to exit from the
pluripotent state in mESCs [20]. miPSCs from p27
knockout mouse showed the same levels of Sox2 and
Nanog expression as that of wild-type miPSCs [29]. Fur-
thermore, we found p27 overexpression did not affect
the differentiation of miPSCs to cardiac myocytes. These
results suggest that overexpression of p27 is a novel ex-
perimental approach for suppression of tumorigenicity
by pluripotent stem cells without affecting pluripotency.
It has been reported that the EBs from skeletal muscle
cell-derived miPSCs attenuated infarct size and im-
proved cardiac function when injected into infarcted
hearts [23], and our results support that miPSCs-p27
were equally effective. Thus miPSCs-p27 after enhancing
expression of cardiac genes with pharmacological or
hypoxic preconditioning may become potential candi-
dates for myogenesis in the infarcted hearts with limited
chances of tumor formation. Pluripotent stem cells are
not only useful to replenish dying cardiac myocytes but
also to protect cardiac myocytes from apoptosis via se-
cretion of paracrine factors [31, 32]. Hence, it is also
more likely that miPSCs-p27 secrete paracrine factors to
protect cardiac myocytes during the critical period of
cell death after infarction.
A close relationship exists between cell cycle and dif-
ferentiation in stem cells. The cdk inhibition promotes
early differentiation in stem cells [25–28]. Furthermore,
artificial cell cycle arrest by the addition of a CDK-2
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inhibitor, roscovitine [33], or genotoxic reagents [34] in-
duces rapid differentiation of stem cells. Therefore, the
overexpression of p27 makes them able to induce differ-
entiation by inhibition of the cell cycle progression. In
fact, we found faster disappearance of pluripotency
genes in EBs and teratomas by p27 overexpression. Also,
the number of undifferentiated cells in miPSCs-p27 de-
rived teratomas was reduced. These results are consist-
ent with previous studies showing differentiation in
human intestinal epithelial cells and Xenopus primary
neurons by p27 overexpression [35]. Similarly, antiproli-
feration activity and induction of differentiation must be
the key functions of p27 to attenuate teratoma formation
in miPSCs. miPSCs-p27 sometimes made smaller terato-
mas, suggesting that p27 is not a perfect solution to
prevent teratoma formation. miPSCs-p27 is a heteroge-
neous cell line in the context of genomic integration
sites of the transgene. Hence, expression level and tim-
ing of inactivation during differentiation may vary in
each cell, thus increasing the chances of teratoma
formation. Specific genomic locus targeted gene integra-
tion technologies like clustered regularly interspaced
short palindromic repeats (CRISPR)-CRISPR associated
proteins (CRISPR-Cas9) [36], transcription activator-like
effector nucleases (TALEN) [37], and zinc finger nucle-
ases (ZFN) [38] may further improve the genetic modifica-
tions in pluripotent stem cells.
Contrary to the early reduction of pluripotency genes
in miPSCs-p27 during differentiation, we could not ob-
serve any differences in expression of pluripotency genes
in miPSCs and miPSCs-p27 cultured on MEFs. The up-
regulation of the pluripotency genes could be caused by
LIF which is secreted from MEFs [39]. The roles of LIF in
miPSCs-p27 and cell cycle inhibition in the differentiation
of pluripotent stem cells need further investigation.
Conclusions
We conclude that p27 overexpression leads to a reduced
proliferation rate and early loss of stemness during
differentiation of miPSCs. Transplantation of EBs
Fig. 5 Effect of miPSCs-p27 on functional recovery of ischemic heart in vivo. a, b Histologic assessment of LV cross section after Masson’s
trichrome staining which stained visible scar region as blue. Infarction size was significantly reduced in miPSC and miPSC-p27 injection groups as
compared with the DMEM injected group showing extensive scar formation. *P < 0.05. c–e Functional recovery of LV was significantly improved
by miPSC and miPSC-p27 transplantation, whereas DMEM transplantation groups showed loss of function as analyzed by (c) LV end-diastolic
volume (LVDEV), d LV end-systolic volume (LVESV), and (e) LV ejection fraction (LVEF) using echocardiography. *P < 0.05. miPSC mouse induced
pluripotent stem cell, miPSCs-p27 p27 overexpressing mouse induced pluripotent stem cells
(See figure on previous page.)
Fig. 4 Teratoma formation of p27 expressing pluripotent stem cells. a–f Representative images of sections from miPSCs or miPSCs-p27 derived
teratomas. Hematoxylin and eosin staining of teratoma derived from miPSCs (a–c) and miPSCs-P27 (d–f). Teratomas contained tissues derived
from all three germ layers. g, h Teratomas were formed by subcutaneous injection of miPSCs (g) and miPSCs-p27 (h) into nude mice. i, j Teratomas
from miPSCs (i) and miPSCs-p27 (j) injected nude mice. k Average weight of teratomas from miPSC and miPSC-p27 injected nude mice.
l, m Expression of pluripotent marker genes are shown. RT-PCR analysis of stem cell marker genes (l) and relative intensities (m) of
miPSCs and miPSCs-p27 are shown. Error bars correspond to the SEM (n = 3). *P < 0.05, student’s t-test. miPSC mouse induced pluripotent
stem cell, miPSCs-p27 p27 overexpressing mouse induced pluripotent stem cells
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developed from both miPSCs-p27 and miPSCs reduces
the infarction size following LAD ligation but with
smaller-sized teratoma by miPSCs-P27. Further modifi-
cation of miPSCs-p27 as discussed may render these
cells as viable therapeutic options for cell therapy of
myocardial infarction and other diseases.
Additional files
Additional file 1: Table S1. Specific primer sequences for RT-PCR
analyses. (DOCX 12 kb)
Additional file 2: Figure S1. Purification of p27 expressing miPSCs.
Flow cytometric analysis of miPSCs (A), or p27-2A-mRFP stable transfected
miPSCs (miPSCs-p27) before (B) and after (C) purification by cell sorter.
Intensities of mRFP fluorescent were plotted against side scatters (SSC). The
area surrounded by red line in B was sorted. (PDF 348 kb)
Additional file 3: Figure S2. Effects of p27 overexpression on EB
formation. Percentages of wells which have EBs and beating EBs are
shown in A and B, respectively. Error bars correspond to the SEM (n = 3).
*P < 0.05, student’s t-test. (PDF 341 kb)
Additional file 4: Figure S3. Expression profile of stem cell factors in
miPSCs-p27. RT-PCR analysis of stem cell marker genes (A) and relative
intensities (B) of miPSCs and miPSCs-p27 are shown. Error bars correspond
to the SEM (n = 3). *P < 0.05, student’s t-test. (PDF 311 kb)
Additional file 5: Figure S4. All teratomas from miPSCs or miPSCs-p27
injected in nude mice. Teratomas from miPSCs and miPSCs-p27 injected
mice are shown (A–D) and (E–H), respectively. (PDF 828 kb)
Additional file 6: Figure S5. Teratoma formations of miPSCs or p27
transient transfected miPSCs injected in nude mice. Phase contrast image
(A) and fluorescent image (B) of miPSCs transfected with p27-2A-mRFP.
Teratomas were shown 4 weeks after transplantation at right hind limb.
miPSCs (C) or p27-2A-mRFP (D) transfected miPSCs were intramuscular
injected into nude mice. (PDF 460 kb)
Abbreviations
cdk: Cyclin dependent kinase; DMEM: Dulbecco’s modified Eagle’s medium;
EB: Embryoid body; ESC: Embryonic stem cell; FACS: Fluorescent active cell
sorting; iPSC: Induced pluripotent stem cell; LAD: Left anterior descending
artery; LIF: Leukemia inhibitory factor; LV: Left ventricle/ventricular; MEF: Mouse
embryonic fibroblast; mESC: Mouse embryonic stem cell; miPSC: Mouse
induced pluripotent stem cell; miPSCs-p27: p27 overexpressing mouse
induced pluripotent stem cells; mRFP: Monomeric red fluorescent protein;
PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TM conceived and designed the experiments, performed experiments
(except myocardial infarction and assays for heart functions), and drafted the
manuscript. HS conceived and designed the experiments and participated in
the experiments of subcutaneous injection of the cells into nude mice, and
drafted the manuscript. MO performed myocardial infarction and assays for
heart functions, and drafted the manuscript. KM conceived and designed the
experiments, and drafted the manuscript. MA conceived and designed the
experiments, drafted the manuscript, supervised, and financially supported
the study. All authors read and approved the final manuscript.
Acknowledgments
We are grateful to Dr. Atsushi Miyawaki at BSI RIKEN for donating the
plasmid to express mVenus-hGeminine. We are grateful to Drs. Yigang Wang
and Meifeng Xu at University of Cincinnati for technical help and donating
materials. This work was supported by National Institutes of Health grants
R37-HL074272, HL 107957 and HL 126516 (MA). The funding agency had no
role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript
Author details
1Department of Pathology and Laboratory Medicine, University of Cincinnati,
Cincinnati, OH 45267-0529, USA. 2Laboratory for Developmental
Neurobiology, RIKEN Brain Science Institute, Saitama 351-0198, Japan.
3Department of Pharmacology, University of Illinois at Chicago College of
Medicine, 835 South Wolcott Ave, Chicago, IL 60612, USA.
Received: 7 June 2015 Revised: 26 November 2015
Accepted: 20 January 2016
References
1. Xu XL, Yi F, Pan HZ, Duan SL, Ding ZC, Yuan GH, et al. Progress and
prospects in stem cell therapy. Acta Pharmacol Sin. 2013;34:741–6.
2. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe
regenerative medicine. Stem Cells. 2009;27:1050–6.
3. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG, et al.
SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived
from human pluripotent stem cells. Nat Biotechnol. 2011;29:1011–8.
4. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, et al. An antibody
against SSEA-5 glycan on human pluripotent stem cells enables removal of
teratoma-forming cells. Nat Biotechnol. 2011;29:829–34.
5. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J. G1 control in
mammalian cells. J Cell Sci Suppl. 1994;18:69–73.
6. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of
G1-phase progression. Genes Dev. 1999;13:1501–12.
7. Zhang H, Hannon GJ, Casso D, Beach D. p21 is a component of active cell
cycle kinases. Cold Spring Harb Symp Quant Biol. 1994;59:21–9.
8. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et
al. New functional activities for the p21 family of CDK inhibitors. Genes Dev.
1997;11:847–62.
9. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The
p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-
dependent kinases in murine fibroblasts. EMBO J. 1999;18:1571–83.
10. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice
lacking p27(Kip1) display increased body size, multiple organ hyperplasia,
retinal dysplasia, and pituitary tumors. Cell. 1996;85:707–20.
11. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine
and other tumors. Am J Pathol. 1997;150:401–7.
12. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its
deregulation in cancer. J Cell Physiol. 2000;183:10–7.
13. Nickeleit I, Zender S, Kossatz U, Malek NP. p27kip1: a target for tumor
therapies? Cell Div. 2007;2:13.
14. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of
S-phase kinase-interacting protein 2, human F-box protein, correlates with
poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001;61:7044–7.
15. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al.
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small
cell lung cancer. Cancer Res. 1997;57:3381–5.
16. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, et al.
p27KIP1 in human lung cancers: differential changes in small cell and
non-small cell carcinomas. Cancer Res. 1998;58:1042–7.
17. Chen J, Willingham T, Shuford M, Nisen PD. Tumor suppression and
inhibition of aneuploid cell accumulation in human brain tumor cells by
ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
J Clin Invest. 1996;97:1983–8.
18. Jiang F, Caraway NP, Li R, Katz RL. RNA silencing of S-phase kinase-interacting
protein 2 inhibits proliferation and centrosome amplification in lung cancer
cells. Oncogene. 2005;24:3409–18.
19. Menchon C, Edel MJ, Izpisua Belmonte JC. The cell cycle inhibitor p27Kip(1)
controls self-renewal and pluripotency of human embryonic stem cells by
regulating the cell cycle. Brachyury and Twist Cell Cycle. 2011;10:1435–47.
20. Li VC, Ballabeni A, Kirschner MW. Gap 1 phase length and mouse embryonic
stem cell self-renewal. Proc Natl Acad Sci U S A. 2012;109:12550–5.
21. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et
al. Visualizing spatiotemporal dynamics of multicellular cell-cycle
progression. Cell. 2008;132:487–98.
22. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. A
monomeric red fluorescent protein. Proc Natl Acad Sci U S A. 2002;99:7877–82.
23. Pasha Z, Haider H, Ashraf M. Efficient non-viral reprogramming of myoblasts
to stemness with a single small molecule to generate cardiac progenitor
cells. PLoS One. 2011;6:e23667.
Matsu-ura et al. Stem Cell Research & Therapy  (2016) 7:30 Page 11 of 12
24. Ahmed RP, Haider HK, Buccini S, Li L, Jiang S, Ashraf M. Reprogramming of
skeletal myoblasts for induction of pluripotency for tumor-free
cardiomyogenesis in the infarcted heart. Circ Res. 2011;109:60–70.
25. Wang X, Yang P. In vitro differentiation of mouse embryonic stem (mES)
cells using the hanging drop method. J Vis Exp. 2008;23:17.
26. Fox MH. A model for the computer analysis of synchronous DNA
distributions obtained by flow cytometry. Cytometry. 1980;1:71–7.
27. Dai Y, Ashraf M, Zuo S, Uemura R, Dai YS, Wang Y, et al. Mobilized bone
marrow progenitor cells serve as donors of cytoprotective genes for cardiac
repair. J Mol Cell Cardiol. 2008;44:607–17.
28. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al.
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential
mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66.
29. Li H, Collado M, Villasante A, Matheu A, Lynch CJ, Cañamero M, et al.
p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation.
Cell Stem Cell. 2012;11:845–52.
30. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer:
prognostic potential and relevance to anticancer therapy. Nat Rev Cancer.
2008;8:253–67.
31. Singla DK, McDonald DE. Factors released from embryonic stem cells inhibit
apoptosis of H9c2 cells. Am J Physiol Heart Circ Physiol. 2007;293:H1590–5.
32. Crisostomo PR, Abarbanell AM, Wang M, Lahm T, Wang Y, Meldrum DR.
Embryonic stem cells attenuate myocardial dysfunction and inflammation
after surgical global ischemia via paracrine actions. Am J Physiol Heart Circ
Physiol. 2008;295:H1726–35.
33. Filipczyk AA, Laslett AL, Mummery C, Pera MF. Differentiation is coupled to
changes in the cell cycle regulatory apparatus of human embryonic stem
cells. Stem Cell Res. 2007;1:45–60.
34. Zanet J, Freije A, Ruiz M, Coulon V, Sanz JR, Chiesa J, et al. A mitosis block
links active cell cycle with human epidermal differentiation and results in
endoreplication. PLoS One. 2010;5:e15701.
35. Quaroni A, Tian JQ, Seth P, Ap Rhys C. p27(Kip1) is an inducer of intestinal
epithelial cell differentiation. Am J Physiol Cell Physiol. 2000;279:C1045–57.
36. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided
human genome engineering via Cas9. Science. 2013;339:823–6.
37. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic
engineering of human pluripotent cells using TALE nucleases. Nat
Biotechnol. 2011;29:731–4.
38. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing
with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–46.
39. Tamm C, Bower N, Anneren C. Regulation of mouse embryonic stem cell
self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J
Cell Sci. 2011;124:1136–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Matsu-ura et al. Stem Cell Research & Therapy  (2016) 7:30 Page 12 of 12
